Can a higher dose of rituximab stop ITP relapses in kids?

This study tests a stronger, more frequent dosing schedule of the drug rituximab in children and young adults (ages 1 to 21) with newly diagnosed immune thrombocytopenic purpura (ITP) who are at high risk for severe bleeding. The goal is to see if this approach can safely improve remission rates and lower the chance of the disease coming back. Participants must have a very low platelet count and at least one high-risk feature, such as being age 10 or older or having active bleeding.